Since tau-PET has not EMA approval in AD yet, lumbar puncture (LP) for both “A” and “T” biomarkers dosage is preferable, when possible, to the sole amyloid-PET, which should be limited to patients showing contraindications to LP [14, 15]. This evidence concerns the gene MAPT and Alzheimer disease.